When we assumed birth-cohort screening in both scenarios,
the ICER of additional DAA treatment compared
with standard treatment alone was $39 600 per QALY saved when we assumed an SVR probability of 0.70; the
ICER was $337 000 per QALY saved when we assumed an
SVR probability of 0.38 (data not shown). The ICER of
additional DAA treatment compared with standard treatment
alone was $19 600 when we assumed the costs were
half our baseline value and was $114 200 when we assumed
the costs were 50% higher.